Jones, Suzanne F.

Phase 1, open-label, dose-escalation, and pharmacokinetic study of STAT3 inhibitor OPB-31121 in subjects with advanced solid tumors

Bendell, J. C., Hong, D. S., Burris, H. A., Naing, A., Jones, S. F., Falchook, G., Bricmont, P., Elekes, A., Rock, E. P., & Kurzrock, R. (2014) · Cancer Chemotherapy and Pharmacology

Cytokine Signaling Pathways and InteractionsLung Cancer Treatments and Mutations

Cited by 115

Phase Ib study of the MEK inhibitor cobimetinib (GDC-0973) in combination with the PI3K inhibitor pictilisib (GDC-0941) in patients with advanced solid tumors

Shapiro, G. I., LoRusso, P., Kwak, E., Pandya, S., Rudin, C. M., Kurkjian, C., Cleary, J. M., Pilat, M. J., Jones, S., de Crespigny, A., et al. (2020) · Investigational New Drugs

PI3K/AKT/mTOR signaling in cancerMelanoma and MAPK Pathways

Cited by 90

Abstract P6-11-09: heavily pre-treated breast cancer patients show promising responses in the first in human study of the first-In-class fatty acid synthase (FASN) inhibitor, TVB-2640 in combination with paclitaxel

Brenner, A., Falchook, G., Patel, M., Infante, Jr., Arkenau, H.-T., Dean, E., Borazanci, E., Lopez, J., Moore, K., Schmid, P., et al. (2017) · Cancer Research

Cancer, Lipids, and MetabolismBreast Cancer Treatment Studies

Cited by 19